Caroline serves as vice president of corporate development at Latigo Biotherapeutics, where she leads business development, corporate strategy, and new product planning. Caroline brings more than a decade of experience to her role, including commercial planning across five therapeutic areas and transactions totaling $15 billion across mergers and acquisitions (M&A) and strategic capital formation.

Prior to Latigo, Caroline held roles of increasing responsibility at Cerevel Therapeutics, most recently leading business development through the company’s $8.7 billion acquisition by AbbVie. Caroline joined Cerevel as one of the first 20 employees and drove multiple mission-critical strategic planning and capital formation projects, including a $125 million project financing for Cerevel’s Phase 3 Parkinson’s program. Earlier in her career, Caroline worked in corporate development at Sangamo Therapeutics and in investment banking at Citigroup.

Caroline holds an MBA from Harvard Business School and a B.A. in Neuroscience and Economics, Magna Cum Laude from Wellesley College.